Articles

The Next Billion-Dollar Track After Short Dramas: This AI Company Is Already the Market Leader | A Conversation with Miao Zhuang, Founder of Jellyfish Intelligence

The Next Billion-Dollar Track After Short Dramas: This AI Company Is Already the Market Leader | A Conversation with Miao Zhuang, Founder of Jellyfish Intelligence

After raising 100 million RMB from top-tier investors, it abruptly abandoned its core business and went all-in on "AI manhua dramas" — an atypical pivot for an AI startup.

Triastek Secures China's First 3D-Printed Drug Manufacturing License, Marking a New Era of Digital Innovation in Chinese Pharma | DaoTong Family

Triastek Secures China's First 3D-Printed Drug Manufacturing License, Marking a New Era of Digital Innovation in Chinese Pharma | DaoTong Family

In September 2025, **Triastek, a Dalton Venture portfolio company, received the nation's first Pharmaceutical Manufacturing License for 3D-printed drug production issued by the Jiangsu Provincial Medical Products Administration**. This marks the first time that 3D printing pharmaceutical technology in China has achieved compliant, regulated manufacturing. It represents a critical step forward for Triastek in drug R&D and industrialization, as well as another milestone for Dalton Venture's investments in pharmaceutical innovation.